4D Molecular Therapeutics, Inc. - Common Stock, par value $0.0001 per share (FDMT)

Historical Holders from Q4 2020 to Q4 2025

Type / Class
Equity / Common Stock, par value $0.0001 per share
Symbol
FDMT on Nasdaq
Shares outstanding
46,691,176
Price per share
$7.50
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares as of 30 Sep 2025
39,480,310
Holdings value
$343,063,021
% of all portfolios
0%
Share change
-867,177
Value change
-$4,202,041
Average buys %
+0%
Average sells %
-0%
Number of holders
128
Price from insider filings
$8.68
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of 4D Molecular Therapeutics, Inc. - Common Stock, par value $0.0001 per share (FDMT) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
BIOTECHNOLOGY VALUE FUND L P 10% 0% $12,276,785 -$534,102 4,632,749 -4.2% BVF PARTNERS L P/IL 31 Mar 2025
RA CAPITAL MANAGEMENT, L.P. 9.9% $12,096,898 4,564,867 RA Capital Management, L.P. 31 Dec 2024
GOLDMAN SACHS GROUP INC 9.6% $11,722,104 4,423,435 THE GOLDMAN SACHS GROUP, INC. 31 Dec 2024
Novo Holdings A/S 6.8% $27,590,750 3,175,000 Novo Holdings A/S 13 Oct 2025
BlackRock, Inc. 6.6% -15% $26,613,959 -$4,803,137 3,062,596 -15% BlackRock, Inc. 30 Sep 2025
JANUS HENDERSON GROUP PLC 4.9% $5,968,436 2,252,240 JANUS HENDERSON GROUP PLC 31 Dec 2024
Venrock Healthcare Capital Partners III, L.P. 1.5% -82% $1,795,640 -$6,028,143 677,600 -77% Venrock Healthcare Capital Partners III, L.P. 31 Mar 2025
Deep Track Capital, LP 1.3% $1,616,235 609,900 Deep Track Capital, LP 31 Dec 2024
As of 30 Sep 2025, 4D Molecular Therapeutics, Inc. - Common Stock, par value $0.0001 per share (FDMT) has 128 institutional shareholders filing 13F forms. They hold 39,480,310 shares of 46,691,176 outstanding shares (85%) .

Top 25 institutional shareholders own 76% of the company.

Filer Ownership Nb Shares Share Change % Portfolio % Holdings Value
BVF INC/IL 9.9% 4,629,289 0% 1.6% $40,228,521
RA CAPITAL MANAGEMENT, L.P. 9.8% 4,563,211 0% 0.49% $39,654,304
GOLDMAN SACHS GROUP INC 8.8% 4,128,416 -0.74% 0.01% $35,875,935
BlackRock, Inc. 8.3% 3,869,130 -3.5% 0% $33,622,738
VANGUARD GROUP INC 5.5% 2,575,122 -5.9% 0% $22,377,810
NOVO HOLDINGS A/S 4.3% 2,000,000 0% 1.1% $17,380,000
JANUS HENDERSON GROUP PLC 3.8% 1,753,367 -0.06% 0.01% $15,236,691
FEDERATED HERMES, INC. 3.4% 1,594,832 -4.3% 0.02% $13,859,090
MILLENNIUM MANAGEMENT LLC 2.5% 1,149,401 -23% 0.01% $9,988,295
ARMISTICE CAPITAL, LLC 2.3% 1,096,000 +265% 0.3% $9,524,240
GEODE CAPITAL MANAGEMENT, LLC 2% 913,519 -0.55% 0% $7,940,280
STATE STREET CORP 1.9% 903,774 -6% 0% $7,853,796
MORGAN STANLEY 1.8% 835,911 -9.6% 0% $7,264,066
BANK OF AMERICA CORP /DE/ 1.8% 819,266 -8.7% 0% $7,119,421
Assenagon Asset Management S.A. 1.4% 663,657 +2.3% 0.01% $5,767,179
TWO SIGMA ADVISERS, LP 1.2% 549,700 -26% 0.01% $4,776,893
DEUTSCHE BANK AG\ 1.2% 543,331 +139% 0% $4,721,546
JPMORGAN CHASE & CO 1.1% 513,515 -42% 0% $4,462,445
ArrowMark Colorado Holdings LLC 1.1% 504,115 -2% 0.08% $4,380,759
RAYMOND JAMES FINANCIAL INC 1% 471,270 +3.5% 0% $4,095,336
NORTHERN TRUST CORP 0.72% 335,586 +2% 0% $2,916,243
Peapod Lane Capital LLC 0.69% 322,081 +1.1% 2.5% $2,798,683
RENAISSANCE TECHNOLOGIES LLC 0.67% 313,186 +169% 0% $2,721,586
CHARLES SCHWAB INVESTMENT MANAGEMENT INC 0.66% 305,857 +3.7% 0% $2,657,897
TWO SIGMA INVESTMENTS, LP 0.59% 273,496 -49% 0% $2,376,680

Institutional Holders of 4D Molecular Therapeutics, Inc. - Common Stock, par value $0.0001 per share (FDMT) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price Investors
2025 Q4 314,050 $2,354,894 -$2,636,178 $7.50 5
2025 Q3 39,480,310 $343,063,021 -$4,202,041 $8.69 128
2025 Q2 40,399,426 $151,027,289 -$9,235,486 $3.71 118
2025 Q1 43,058,381 $139,823,530 -$22,403,353 $3.23 122
2024 Q4 46,814,756 $260,641,875 -$76,311,870 $5.57 139
2024 Q3 57,424,056 $620,702,412 -$40,136,853 $10.81 134
2024 Q2 57,308,865 $1,203,054,094 +$3,358,870 $20.99 140
2024 Q1 56,168,310 $1,788,899,461 +$448,964,347 $31.86 147
2023 Q4 15,880 $321,729 $20.26 1
2023 Q3 41,907,339 $533,477,373 +$919,000 $12.73 109
2023 Q2 41,245,744 $745,276,471 +$197,025,577 $18.07 99
2023 Q1 30,402,249 $522,307,520 +$34,998,616 $17.19 92
2022 Q4 27,996,450 $621,773,974 +$47,620,034 $22.21 95
2022 Q3 22,811,889 $183,402,797 -$11,574,269 $8.04 80
2022 Q2 24,674,539 $172,109,260 +$978,008 $6.98 83
2022 Q1 25,274,573 $382,194,957 +$19,406,035 $15.12 70
2021 Q4 23,391,123 $513,008,297 +$75,322,119 $21.94 72
2021 Q3 18,780,707 $504,776,012 +$68,608,646 $26.97 61
2021 Q2 16,170,891 $389,389,000 -$3,186,320 $24.08 52
2021 Q1 15,384,544 $664,817,567 +$47,822,437 $43.38 64
2020 Q4 12,998,649 $536,346,000 +$512,395,926 $41.45 50